TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric subjects with JIA aged from 2 to less than 18 years who met entry criteria for the qualifying/index study and in the opinion of the investigator have sufficient evidence of JIA disease activity to warrant use of tofacitinib as a DMARD. Subjects turning 18 years of age during participation in the qualifying/index study or subsequently will be eligible for participation in this study.~* The subject has discontinued disallowed concomitant medications for the required time prior to the first dose of study drug, as defined in Appendix 1, and is taking only those concomitant medications in doses and frequency allowed by the protocol.~* Fertile male subjects and female subjects of childbearing potential who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must be using a highly effective method of contraception as outlined in this protocol throughout the study and for at least 28 days after the last dose of study medication.~* Subjects must have previously completed participation in a qualifying study of tofacitinib for the treatment of JIA. Subjects who have required earlier discontinuation of treatment in a qualifying study for reasons other than tofacitinib related serious adverse events may be eligible.~Exclusion Criteria:~* persistent oligoarthritis, and undifferentiated JIA.~* Infections:~  1. Chronic infections.~ 2. Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 3 months prior to the first dose of study drug.~ 3. Any treated infections within 2 weeks of baseline visit.~ 4. A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus.~ 5. History of infected joint prosthesis with prosthesis still in situ.~* History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): All patients will be in tofacitinib treatment group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 weeks through exactly 12 weeks~* Healthy infants~Exclusion Criteria:~* Clinical evidence of active gastrointestinal illness~* Fever, with a rectal temperature of greater than and equal to thirty eight degree celsius at the time of immunization~* History of congenital abdominal disorders, intussusception, or abdominal surgery~* History of known prior rotavirus disease~* Known or suspected impairment of immunological function~* Prior administration of any rotavirus vaccine~* Known hypersensitivity to any component of the rotavirus vaccine, e.g. trypsin

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- RotaTeq™ Vaccine (V260) (Type: EXPERIMENTAL): Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically, cytogenetically, or immunophenotypically confirmed Burkitt's leukemia or Burkitt's or Burkitt-like lymphoma~  * L3 morphology surface IgG expression~ * Cytogenetic evidence for t(8;14), t(8;22), or t(2;8)~* Previously untreated disease except hydroxyurea for leukocytosis~* CNS involvement allowed~* Patients with Burkitt's leukemia or Burkitt's lymphoma with bone marrow involvement must also be enrolled on CALGB-8461~* Patients with Burkitt's leukemia must also be enrolled on CALGB-9665~PATIENT CHARACTERISTICS:~Age:~* 16 and over~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~Renal:~* Creatinine no greater than 1.5 times ULN~Other:~* HIV negative~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent interleukin-11~Chemotherapy:~* See Disease Characteristics~* No other concurrent chemotherapy~Endocrine therapy:~* No concurrent hormonal therapy except for non-disease-related conditions (e.g., insulin for diabetes)~* No concurrent steroids except for adrenal failure~Radiotherapy:~* No concurrent palliative radiotherapy except whole-brain irradiation for documented CNS disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab with High Intensity Chemotherapy (Type: EXPERIMENTAL): Cycle1: Cyclophosphamide 100 mg/m\^2/day (d) IV (d 1-5), Prednisone 60 mg/m\^2/d oral (d 1-7), Allopurinal 300 mg/d oral (d 1-14) Cycle 2, 4 \& 6 (21 day): Ifosfamide 800 mg/m\^2/d (d 1-5), Dexamethasone 10 mg/m\^2/d (d1-5), Methotrexate 150 mg/m\^2 load, then 1.35 g/m\^2 over 23.5 h (d 1), Leucovorin 25 mg/m\^2 36 h after methotrexate (d 2) then 10 mg/m\^2 every 6 h, Vincristine 2 mg push (d 1), Cytarabine 1000 mg/m\^2/d over 2 h (d 4-5), Etoposide 80 mg/m\^2.d over 1 h (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 50 mg/m\^2 d 8 cycle 2 only, 375 mg/m\^2/d (d 10, 12 cycle 2, d 8 cycle 4 \& 6) Cycle 3, 5 \& 7 (21 day): Cyclophosphamide 200 mg/m\^2/day (d) IV (d 1-5), Dexamethasone 10 mg/m\^2/d (d1-5), Methotrexate 150 mg/m\^2 load, then 1.35 g/m\^2 over 23.5 h (d 1), Leucovorin 50 mg/m\^2 36 h after methotrexate (d 2) then 10 mg/m\^2 every 6 h, Vincristine 2 mg push (d 1), Doxorubicin 25 mg/m\^2/d (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 375 mg/m\^2/d (d 8)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Aripiprazole in the Treatment of CD in Adolescents

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder.~Exclusion Criteria:~* Clinically significant laboratory and/or ECG abnormalities~* Pre-existing health conditions that would compromise patient safety~* Mental retardation~* Previous use of aripiprazole~* Active psychosis

- Gender: MALE
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Adolescent Conduct Disorder Males (Type: OTHER): All subjects were male and had a diagnosis of conduct disorder. All subjects were offered treatment with aripiprazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Corticoids in Severe Community-Acquired Pneumonia (CAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe community-acquired pneumonia Fine V~* CRP \>=15 mg/100 mL~Exclusion Criteria:~* Major contraindications for corticosteroids, such as uncontrolled diabetes, immunosuppression~* Previous glucocorticoid treatment during the previous month~* Documented extrapulmonary infection~* Previous hospitalization in the previous month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methylprednisolone (Type: EXPERIMENTAL): methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Moderate to severe plaque-type psoriasis diagnosed for at least 6 months;~2. Subjects with moderate-to-severe plaque psoriasis at baseline, who were defined as follows: Body Surface Area (BSA) ≥ 10%, PASI ≥ 12 and SPGA score ≥ 3;~3. Subjects with a history of systemic therapy or phototherapy for psoriasis at least once before, or suitable to receive systemic therapy or phototherapy for psoriasis assessed by investigator;~4. Women of childbearing age is not pregnant or lactating, and the subjects and their partners voluntarily take contraceptive measures considered effective by the investigator during the treatment period and at least 6 months after the last receipt of the study drug.~Exclusion Criteria:~1. Forms of psoriasis other than chronic plaque-type psoriasis;~2. History or evidence of active/latent tuberculosis;~3. Positive results of confirmatory serology test for hepatitis B, hepatitis C,HIV or syphilis at screening;~4. History of serious infection within 2 months before screening;~5. History of malignancy of any organ system;~6. Inadequate washout period for prior psoriatic therapy;~7. Previous use of secukinumab, ixekizumab or any other drug that targets IL-17 or IL-17 receptor;~8. Any medical conditions, in the opinion of the investigator, would place the subject at risk, interfere with study participation or study results interpretation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- AK111 regimen (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 20-70 years~* Good performance status (Zubrod score \< 2)~* No serious underlying disease~* Normal renal function test~* Normal liver function test~* Platinum based chemotherapy is the first line regimen~* No prior or receiving radiotherapy~Exclusion Criteria:~* Iron hypersensitivity~* Underlying disease which has the risk of iron overload such as chronic kidney disease, major thalassemia~* Progressive disease~* Bone marrow metastasis

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous iron (Type: EXPERIMENTAL): Iron sucrose 200 mg intravenous infusion in 15 minutes
- Oral iron (Type: PLACEBO_COMPARATOR): Ferrous fumarate 200 mg oral three times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a clinical diagnosis of BKC in at least one eye~* Subjects must be willing to discontinue contact lens use for the duration of the study~* Subjects who are able and willing to comply with all treatment and follow- up/study procedures.~Exclusion Criteria:~* Subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.~* Subjects who have any uncontrolled systemic disease or debilitating disease.~* Subjects who have a known hypersensitivity to the study drugs or their components (including benzalkonium chloride) or contraindications to tobramycin or ocular corticosteroids.~* Subjects who use any topical or systemic ophthalmic medications listed as disallowed in the study protocol, within the specified time frame prior to Visit 1.~* Subjects who have a disease or conditions which the Investigator determines could interfere with the safety and efficacy evaluations of the study drug.~* Subjects having ocular surgery (including laser surgery) in either eye within the past three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loteprednol and tobramycin (Type: EXPERIMENTAL): Loteprednol etabonate and tobramycin ophthalmic suspension
- Tobramycin and dexamethasone (Type: ACTIVE_COMPARATOR): Tobramycin and dexamethasone ophthalmic suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesia For Positioning Patient With Femur Fracture For Spinal Anaesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anaesthesiologists (ASA) score I and II~* Elective surgery of repair of unilateral, single femoral fracture under spinal anaesthesia performed in General Operation Theatre, Hospital Kuala Lumpur. The fracture may involve femoral neck or femoral shaft.~Exclusion Criteria:~* Patient with contraindication for spinal anaesthesia~* Known hypersensitivity or contraindication to medication used in this study~* Morbid obesity (body mass index (BMI) \> 35 kg/m2)~* Infection at the intended site of administration of fascia iliaca compartment block~* Patient with impaired cognitive function

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- fascia iliaca compartment block (Type: ACTIVE_COMPARATOR): Patient will receive 40ml of ropivacaine 0.375% at the fascia iliaca compartment under the guidance of ultrasound. It will be given 20 minutes before patient is positioned for spinal anaesthesia
- intravenous fentanyl (Type: ACTIVE_COMPARATOR): Patient will receive 0.5 mcg/kg of intravenous fentanyl. It will be given 5 minutes before patient is positioned for spinal anaesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Darvadstrocel for Crohn's Fistula in the Realworld

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1)complex fistula in a patient with CD~* 2)failure of conventional and anti-tumour necrosis factor treatment~* 3)absence of collection s\>2cm confirmed by pelvic MRI scan at the time of surgery~Exclusion Criteria:~* Patients with a diagnosis of rectovaginal fistula, rectal stenosis or severe active proctitis were excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group of patients treated with darvadstrocel (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 18 to 75 years~2. Have clinical diagnosis of chronic idiopathic urticaria (CIU), chronic idiopathic pruritus (CIP), lichen planus (LP), lichen simplex chronicus (LSC) and plaque psoriasis (PPs) for at least 6 months~3. Moderate to severe pruritus~4. Female participants of childbearing potential must have a negative pregnancy test, be nonlactating, and have agreed to use a highly effective method of contraception, as specified in the protocol, from the Screening Visit until 10 weeks after final study drug administration~5. Able to comprehend and willing to sign an Informed Consent Form and able to abide by the study restrictions and comply with all study procedures for the duration of the study~Exclusion Criteria:~1. Use of prohibited medications within the indicated timeframe from Day 1 to the End of Study~2. Is currently using medication known to cause pruritus~3. Has any inflammatory, pruritic, and/or fibrotic skin condition other than the diagnosis that defines inclusion~4. Laboratory abnormalities that fall outside the windows specified in the protocol at the Screening Visit~5. Has an active infection, including skin infection~6. Any medical or psychiatric condition which, in the opinion of the Investigator or the Sponsor, may place the participant at increased risk as a result of study participation, interfere with study participation or study assessments, affect compliance with study requirements, or complicate interpretation of study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- KPL-716 (Type: EXPERIMENTAL): Weekly for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Weekly for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Behavior Therapy for Work Success in Veterans With Mental Illness: A Pre-post Efficacy Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants include Veterans who are receiving individualized vocational services at an urban Midwestern VA medical center.~* Inclusion criteria are a diagnosis of a mental disorder as confirmed through medical record review, current enrollment in vocational services, and an active goal of working in the community~  * participants may be currently working in the community or unemployed and searching for work~Exclusion Criteria:~* Exclusion criteria is a major cognitive deficit or severe medical condition that would prevent participation in the intervention and/or competitive community work.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cognitive behavior therapy for work success (Type: OTHER): Fifty participants will take part in the 12 week CBTw program. All participants will receive standard SE services during the study. The longitudinal design will consist of assessments of competitive employment outcomes, important psychosocial outcomes, and background and demographic variables at baseline and at two follow-up periods' immediately following the conclusion of the CBTw program and six months after the conclusion of the program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete